NCT05751941 2026-03-16
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
Clinical Trials
75 trialsNCT06632977 2026-03-04
PREDICT
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT03344211 2026-02-27
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer
University of Southern California
Phase 2 Active not recruiting
NCT06099769 2026-02-25
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT01885949 2026-02-24
Tivozanib + Enzalutamide in Adv Prostate Cancer
Massachusetts General Hospital
Phase 2 Terminated
NCT02749903 2026-02-11
Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT05730712 2026-02-06
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT03246347 2026-01-23
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT06734130 2026-01-21
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT03556904 2026-01-15
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT06059118 2026-01-14
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT03809000 2025-12-30
STEEL
RTOG Foundation, Inc.
Phase 2 Active not recruiting
NCT06378866 2025-12-26
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT05873192 2025-12-23
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT02452008 2025-12-19
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT05189457 2025-12-04
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT04335682 2025-11-04
ARACOG
Alliance Foundation Trials, LLC.
Phase 2 Active not recruiting
NCT06844383 2025-10-29
TALENT
Prostate Cancer Clinical Trials Consortium
Phase 2 Recruiting
NCT02203695 2025-10-28
Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT06499870 2025-10-21
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Northwestern University
Phase 2 Recruiting
NCT05081193 2025-09-22
Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT06922318 2025-09-17
The COSMYC Trial (COmbined Suppression of MYC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT04015622 2025-08-20
PROTRACT
British Columbia Cancer Agency
Phase 2 Active not recruiting
NCT01990196 2025-08-17
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04471974 2025-07-22
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Active not recruiting
NCT04363164 2025-07-14
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT02955394 2025-07-09
Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
University of Colorado, Denver
Phase 2 Active not recruiting
NCT02750358 2025-06-22
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06312670 2025-05-29
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02278185 2025-05-11
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
University of Colorado, Denver
Phase 2 Completed
NCT04332744 2025-05-11
ZZ-First
MedSIR
Phase 2 Completed
NCT04262154 2025-04-27
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03314324 2025-04-17
ODENZA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT02684227 2025-03-19
Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05393791 2024-11-26
ANZadapt
Leiden University Medical Center
Phase 2 Recruiting
NCT05404139 2024-11-25
DIRECT
University Health Network, Toronto
Phase 2 Recruiting
NCT04207255 2024-09-25
Addition of Opaganib to Androgen Antagonists in Patients With mCRPC
Medical University of South Carolina
Phase 2 Completed
NCT02689427 2024-09-19
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03336983 2024-08-01
BonEnza
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2 Completed
NCT03770455 2024-07-09
Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC
Tulane University
Phase 2 Terminated
NCT02676986 2024-07-05
ARB
Queen Mary University of London
Phase 2 Completed
NCT02453009 2024-05-30
CHEIRON
Santa Chiara Hospital
Phase 2 Completed
NCT03700099 2024-04-15
Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide
Instituto do Cancer do Estado de São Paulo
Phase 2 Active not recruiting
NCT02903160 2024-02-07
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT04419402 2024-02-07
ENZA-p
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT02640534 2023-06-27
Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone
Swiss Cancer Institute
Phase 2 Terminated
NCT01974765 2023-04-28
Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03464201 2023-02-22
GREKO III
Grupo Español de Tumores Huérfanos e Infrecuentes
Phase 2 Completed
NCT04142060 2022-10-28
ARIANNA
SOLTI Breast Cancer Research Group
Phase 2 Terminated
NCT02268175 2022-04-19
Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Dana-Farber Cancer Institute
Phase 2 Completed